Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-08-18 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金管理制度" which translates to "Fundraising Capital Management System" or "Management System for Raised Funds." It details the company's internal rules and procedures for managing and using raised funds, including storage, usage, supervision, and responsibilities. It references regulatory laws and stock exchange rules, outlines board and shareholder meeting approvals, and describes internal controls and reporting requirements. The document is a detailed policy or governance document related to capital management rather than a financial report, announcement, or presentation. It is not an announcement of a report, nor a certification or legal proceeding. It fits best under Capital/Financing Update (CAP) as it concerns the management and use of capital raised by the company, including compliance and supervisory mechanisms. The document length (5834 characters) supports it being a substantive policy document rather than a brief announcement. Therefore, the classification is CAP with high confidence.
2025-08-18 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions (关联交易管理制度) of Anhui Xuyi Pharmaceutical Co., Ltd. It details the company's internal rules and procedures regarding related party transactions, including definitions, principles, approval processes, pricing, and responsibilities. The document includes board meeting dates and voting results related to the approval of this internal management system. It is a governance-related document outlining internal rules and policies rather than a financial report, earnings release, or announcement of voting results. It is not a report publication announcement since it contains substantive content of the management system itself. Therefore, the document fits best under Governance Information (CGR).
2025-08-18 Chinese
董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is a detailed internal governance document titled '安徽峆一药业股份有限公司董事会提名委员会工作细则' which translates to 'Board Nomination Committee Working Rules'. It outlines the structure, responsibilities, and procedures of the board nomination committee, referencing relevant laws and company bylaws. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and board committee operations. Therefore, it fits the category of Governance Information (CGR). The document length is 2755 characters, which is sufficient for a detailed governance report rather than a brief announcement.
2025-08-18 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as "安徽峆一药业股份有限公司投资者关系管理制度" which translates to "Investor Relations Management System of Anhui Xuyi Pharmaceutical Co., Ltd." It details the company's internal policies and procedures for managing investor relations, including communication principles, responsibilities, and organizational structure. It is a governance-related document focusing on internal rules and management practices rather than financial results, audit opinions, or announcements of meetings or votes. It does not contain financial statements or earnings data, nor is it a report publication announcement. Therefore, it fits best under Governance Information (CGR). The document length (6483 characters) supports it being a full policy document rather than a brief announcement.
2025-08-18 Chinese
2025年半年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025 年半年度募集资金存放、管理与实际使用情况的专项报告" which translates to a "2025 Semi-Annual Special Report on the Deposit, Management, and Actual Use of Raised Funds." It details the company's fundraising activities, including issuance of new shares, amounts raised, management of the raised funds, usage of funds during the reporting period, changes in the use of funds, and compliance with regulatory requirements. The document includes specific financial figures related to fundraising and usage, references to regulatory approvals, and internal board and shareholder meeting resolutions related to fundraising and fund usage. It is a comprehensive report focused on the management and use of capital raised through equity issuance, not a general financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is about 4819 characters, which is sufficient to be a report rather than a brief announcement. Therefore, the correct classification is CAP with high confidence.
2025-08-18 Chinese
第五届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of several proposals including the cancellation of the Supervisory Board, changes to the company's articles of association, and approval of the 2025 semi-annual report and related reports. The document does not contain the actual semi-annual report or financial statements but references that these reports are disclosed separately on the Beijing Stock Exchange information platform. The document is a formal announcement of meeting resolutions and approvals, not the report itself. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement of board resolutions and approvals without substantive financial data included.
2025-08-18 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.